BenevolentAI (previously Stratified Medical) is a leading artificial intelligence company that combines advanced AI and machine learning with cutting edge science to decipher complex disease biology, generate novel insights and discover more effective medicines.
BenevolentAI aims to accelerate the journey from inventive ideas to medicines for patients by developing AI to generate new treatments for some of the world’s 8,000 untreated diseases.
BenevolentAI was founded in 2013 by Ken Mulvany. The company is headquartered in London with a research facility in Cambridge (UK) and a further office in New York.
BenevolentAI's unique computational R&D platform spans every step of the drug discovery process, powering an in-house pipeline of 25+ drug programmes from early discoverytowards clinical phases.
BenevolentAI, with several successful collaborations with leading pharmaceutical organisations, is also the only AI-drug discovery company with a clinically validated approach, having discovered a leading repurposed drug candidate for COVID-19.
BenevolentAI is backed by Temasek Holdings, Goldman Sachs, Woodford Investment Management, Lansdowne Partners, and others. The company has raised a total of $297M in funding to date. BenevolentAI was reportedly valued at $1B from a financing raised in Sep 2019.